TITLE 1 KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab
AUTHORS 1 Lièvre A, Bachet J-B, Boige V et al.
JOURNAL 1 J Clin Oncol 2008; 26:374–9.
TITLE 2 Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
AUTHORS 2 Amado RG, Wolf M, Peeters M et al.
JOURNAL 2 J Clin Oncol 2008; 26:1626–34.
Declaration of Interests The author is the local principal investigator for the COIN and PICCOLO studies and has received funding and an educational grant from Merck.
